In this situation, the accumulation of DNA damage might be sufficient to induce cell death (apoptosis), and clinical trials showing the benefits of PARP inhibitors in HRD cancers support this concept 4,5. The gene discussed is PARP1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.